Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 4/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.33 |
| ▸ | LOX | P28300 | 1/20 | 0.33 |
| ▸ | PNMT | P11086 | 2/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.30 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20818377 | 0.81 | L3MBTL1 (0.46) | ALDH1A1L3MBTL1HCRTR1HCRTR2CXCR4 | |
| SCHEMBL20818450 | 0.81 | ALDH1A1 (0.33) | DPP4ALDH1A1L3MBTL1HCRTR1HCRTR2 | |
| SCHEMBL2491544 | 0.80 | DPP4 (0.47) | DPP4LOXL2ALDH1A1L3MBTL1PNMT | |
| SCHEMBL22719069 | 0.75 | KDM1A (0.40) | ALDH1A1L3MBTL1HCRTR1HCRTR2MAOB | |
| SCHEMBL16547434 | 0.75 | DPP4 (0.43) | DPP4LOXL2ALDH1A1L3MBTL1PNMT | |
| SCHEMBL3287856 | 0.75 | DPP4 (0.43) | DPP4LOXL2ALDH1A1L3MBTL1PNMT | |
| SCHEMBL30852121 | 0.74 | ALDH1A1 (0.33) | DPP4ALDH1A1L3MBTL1HCRTR1HCRTR2 | |
| SCHEMBL2348709 | 0.73 | DPP4 (0.42) | DPP4LOXL2LOXPNMTADRB2 | |
| SCHEMBL22719100 | 0.73 | HDAC1 (0.39) | DPP4ALDH1A1L3MBTL1HCRTR1HCRTR2 | |
| SCHEMBL30391768 | 0.73 | BACE1 (0.42) | ALDH1A1L3MBTL1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12435078-B2 | Pyridazinones and methods of use thereof | GFB (ABC), LLC (US) | 2025-10-07 | — | — | US | disclosed |
| US-20230203028-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2023-06-29 | — | — | US | disclosed |
| US-20230203028-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2023-06-29 | — | — | US | disclosed |
| US-20230203028-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2023-06-29 | — | — | US | disclosed |
| EP-3684364-A2 | PYRIDAZINONES AND METHODS OF USE THEREOF | Goldfinch Bio, Inc. (US) | 2020-07-29 | — | — | EP | disclosed |
| WO-2019055966-A2 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. (US) | 2019-03-21 | — | — | WO | disclosed |
| WO-2019055966-A2 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. (US) | 2019-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203028-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | PDXK, ATP6V1B1, REN | DPP4 1307/4885LOXL2 1797/4885ALDH1A1 649/4885 |
| US-12435078-B2 | Pyridazinones and methods of use thereof | PDXK, ATP6V1B1, REN | DPP4 1307/4885LOXL2 1797/4885ALDH1A1 649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.